Kittipibul V, Lam CSP (2025) Heart failure with preserved ejection fraction and atrial fibrillation: epidemiology, pathophysiology, and diagnosis interplay. Heart Fail Rev. https://doi.org/10.1007/s10741-025-10488-0
Ariyaratnam JP, Elliott AD, Mishima RS, Gallagher C, Lau DH, Sanders P (2021) Heart failure with preserved ejection fraction: an alternative paradigm to explain the clinical implications of atrial fibrillation. Heart Rhythm O2(2):771–783
Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385:1451–1461
Article CAS PubMed Google Scholar
Solomon SD, McMurray JJV, Claggett B et al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387:1089–1098
Filippatos G, Farmakis D, Butler J et al (2023) Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation. Eur J Heart Fail 25:970–977
Article CAS PubMed Google Scholar
Zelniker TA, Bonaca MP, Furtado RHM et al (2020) Effect of dapagliflozin on atrial fibrillation in patients with type 2 Diabetes mellitus. Circulation 141:1227–1234
Article CAS PubMed Google Scholar
Solomon SD, McMurray JJV, Vaduganathan M et al (2024) Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 391:1475–1485
Article CAS PubMed Google Scholar
Pfeffer MA, Claggett B, Assmann SF et al (2015) Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 131:34–42
Article CAS PubMed Google Scholar
Shantsila E, Shahid F, Sun Y et al (2020) Spironolactone in atrial fibrillation with preserved cardiac fraction: the IMPRESS-AF trial. J Am Heart Assoc 9:e016239
Article CAS PubMed PubMed Central Google Scholar
Alexandre J, Dolladille C, Douesnel L et al (2019) Effects of mineralocorticoid receptor antagonists on atrial fibrillation occurrence: a systematic review, meta-analysis, and meta-regression to identify modifying factors. J Am Heart Assoc 8:e013267
Article PubMed PubMed Central Google Scholar
Ferreira JP, Cleland JG, Girerd N et al (2023) Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials. Eur J Heart Fail 25:108–113
Article CAS PubMed Google Scholar
Yusuf S, Pfeffer MA, Swedberg K et al (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet 362:777–781
Article CAS PubMed Google Scholar
Solomon SD, McMurray JJV, Anand IS et al (2019) Angiotensin-Neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381:1609–1620
Article CAS PubMed Google Scholar
Cikes M, Planinc I, Claggett B et al (2022) Atrial fibrillation in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC Heart Fail 10:336–346
Article CAS PubMed Google Scholar
Ducharme A, Swedberg K, Pfeffer MA et al (2006) Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 152:86–92
Kosiborod MN, Abildstrøm SZ, Borlaug BA et al (2023) Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 389:1069–1084
Article CAS PubMed Google Scholar
Packer M, Zile MR, Kramer CM et al (2025) Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med 392:427–437
Article CAS PubMed Google Scholar
Verma S, Butler J, Borlaug BA et al (2024) Atrial fibrillation and semaglutide effects in obesity-related heart failure with preserved ejection fraction. JACC 84:1603–1614
Article CAS PubMed Google Scholar
Van Gelder IC, Rienstra M, Bunting KV et al (2024) 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). Eur Heart J 45:3314–3414. https://doi.org/10.1093/eurheartj/ehae176
Kirchhof P, Camm AJ, Goette A et al (2020) Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med 383:1305–1316
Rillig A, Magnussen C, Ozga A-K et al (2021) Early rhythm control therapy in patients with atrial fibrillation and heart failure. Circulation 144:845–858
Article CAS PubMed PubMed Central Google Scholar
Parkash R, Wells GA, Rouleau J et al (2022) Randomized ablation-based rhythm-control versus rate-control trial in patients with heart failure and atrial fibrillation: results from the RAFT-AF trial. Circulation 145:1693–1704
Article CAS PubMed Google Scholar
Packer DL, Mark DB, Robb RA et al (2019) Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: The CABANA randomized clinical trial. JAMA 321:1261–1274
Article CAS PubMed PubMed Central Google Scholar
Packer DL, Piccini JP, Monahan KH et al (2021) Ablation versus drug therapy for atrial fibrillation in heart failure. Circulation 143:1377–1390
Article CAS PubMed PubMed Central Google Scholar
Martens P, Augusto SN Jr, Erzeel J, Pison L, Mullens W, Tang WHW (2025) Effects of atrial fibrillation ablation for heart failure with preserved ejection fraction: insights from CABANA. JACC Heart Fail 13:785–794
Article CAS PubMed Google Scholar
Xie Z, Qi B, Wang Z et al (2023) Ablation for atrial fibrillation improves the outcomes in patients with heart failure with preserved ejection fraction. EP Europace 26. https://doi.org/10.1093/europace/euad363
Al-Sadawi M, Aleem S, Aslam F et al (2022) Rhythm versus rate control for atrial fibrillation in heart failure with preserved ejection fraction. Heart Rhythm O2(3):520–525
Sramko M, Wichterle D, Melenovsky V et al (2017) Resting and Exercise-Induced Left Atrial Hypertension in Patients With Atrial Fibrillation: The Causes and Implications for Catheter Ablation. JACC Clin Electrophysiol 3:461–469
Sugumar H, Nanayakkara S, Vizi D et al (2021) A prospective STudy using invAsive haemodynamic measurements foLLowing catheter ablation for AF and early HFpEF: STALL AF-HFpEF. Eur J Heart Fail 23:785–796
Article CAS PubMed Google Scholar
Ariyaratnam JP, Elliott AD, Mishima RS et al (2023) Identification of Subclinical Heart Failure With Preserved Ejection Fraction in Patients With Symptomatic Atrial Fibrillation. JACC Heart Fail 11:1626–1638
Article CAS PubMed Google Scholar
Chacko P, Bhuta S, Meenakshisundaram C, Moustafa A, Davis A, Gupta R (2023) Prevalence of Heart Failure With Preserved Ejection Fraction in Patients Undergoing Atrial Fibrillation Ablation Based on Resting and Post-Tachycardia Pacing Left Atrial Pressure. Am J Cardiol 205:445–450
Chieng D, Sugumar H, Segan L et al (2023) Atrial fibrillation ablation for heart failure with preserved ejection fraction. JACC: Heart Fail 11:646–658. https://doi.org/10.1016/j.jchf.2023.01.008
Joglar JA, Chung MK, Armbruster AL et al (2024) 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 149:e1–e156
Benali K, Khairy P, Hammache N et al (2023) Procedure-Related Complications of Catheter Ablation for Atrial Fibrillation. JACC 81:2089–2099
Comments (0)